Bringing the Next Generation of Peptide Therapeutics to Patients

Nimble Therapeutics is a biotechnology company revolutionizing the discovery & development of peptide therapeutics. Inspired by Nature’s elegance and turbocharged by a paradigm-shifting peptide discovery & development engine, our solutions to drug complex targets are limited only by imagination.

Path 3

Our team has worked together for years to develop Nimble’s proprietary drug discovery and development engine, and exhaustively validated our approach with some of the worlds most respected pharmaceutical companies and academics. Combined with our massively parallel photolithographic synthesis platform, sophisticated assays & powerful analytics, Nimble strives to make the next generation of peptide therapeutics a reality for patients.

Management Team


Jigar Patel, PhD


Cyrus Arman, PhD, MBA


Brad Garcia, PhD


Lauren Goodrich, PhD


John Tan, PhD


Andrew Wagner, MSc


Daniel Agnew, PhD

Board Members

Jigar Patel is founder and CEO of Nimble Therapeutics.  With more than 15 years of experience in the pharmaceutical and biotechnology space, Jigar leads Nimble’s veteran team and champions the company’s game-changing technology for accelerating the discovery and development of peptide therapeutics. Jigar started his drug development career at the Walter Reed Institute of Research supporting a Vaccine and Drug trial for Malaria in Western Kenya. Before founding Nimble, Jigar led an early discovery research team at Roche with collaborations globally with diagnostic and therapeutics divisions across many disease areas. Jigar is an author and inventor on numerous peer reviewed publications and patents in the areas of drug discovery, oncology, immunology and infectious disease. Jigar was trained at Dr. MGR Medical University and at the University of Notre Dame.
Dan is currently a part-time Venture Partner at Decheng Capital and has been with the firm since July 2016. He serves on several Boards on behalf of Decheng Capital and as an Independent Director. Prior to joining Decheng, Dr. Zabrowski worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals. Prior to joining Roche, Dr. Zabrowski worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago. Dr. Zabrowski received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.
Deval has more than 20 years of experience helping to build and grow successful companies. He is currently a partner at Telegraph Hill Partner and serves on several boards. Prior to THP he was a founding Research Director at Synteni, which was acquired by Incyte Genomics. Deval received a BA from the University of California, Berkeley and a PhD from Stanford University and currently serves on the Stanford Medical School Alumni Board of Governors.
Paul is a partner at Telegraph Hill partners.  Before joining THP, he was Head of Strategy and Corporate Development for Life Technologies in a number of key leadership positions. Dr. Grossman has led the acquisition or divestment of more than 25 businesses. Prior to joining Invitrogen, Dr. Grossman held a variety of leadership roles during his more than 20 years at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development. Dr. Grossman received bachelors and Ph.D. degrees in chemical engineering from the University of California, Berkeley, a master’s degree in chemical engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law.
Rob is a partner at Telegraph Hill partners. He has worked in the area of securities law, corporate finance, venture capital and mergers & acquisitions since 1998. Prior to joining THP, he worked in Citigroup Global Markets’ San Francisco office focused on healthcare investment banking and acquisition finance.  Previously, Rob worked at the Securities & Exchange Commission in Los Angeles and the New York-based law firm of Cravath, Swaine & Moore. Rob serves on several Boards on behalf of THP.  Rob received a BS in Geological Sciences and a BA in Economics from UCSB. He received a JD/MBA from Northwestern University School of Law and Kellogg School of Management.


Join our team

Nimble Therapeutics is advancing the discovery and development of peptide therapeutics by combining our proprietary technology with the intellect, creativity, and passion of our dedicated employees. Our success is driven by innovative science, sound business practices, and an inclusive culture. We have built a collaborative, supportive atmosphere where all employees are encouraged to learn and grow. As an employer, we offer competitive compensation packages, a robust, affordable benefit package, generous paid time off, a flexible work environment, and more. Whether you are a scientist, engineer, informaticist, business leader, or administrative professional, your role is critical to Nimble achieving its mission.


Browse our current job openings below, then follow us on LinkedIn to stay up to date on our progress and be the first to know about future job openings.


There are currently no open positions. Please check back soon!


Nimble Therapeutics is an equal opportunity employer.